Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can doctors help families unlock Life-Saving genetic secrets?

NCT ID NCT05772130

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a new way to help family members of cancer patients learn if they have inherited a higher risk for cancer. About 240 people with a known cancer gene change will be asked to share their test results with their close relatives, either on their own or with help from their doctor. The goal is to see if doctor-assisted communication leads to more relatives getting tested and getting the care they need.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing * PATIENTS: Have an pathogenic/ likely pathogenic germline variant * PATIENTS: Fluent in English * PATIENTS: Age \>= 18 years * PATIENTS: Willing to provide contact information for eligible first-degree relatives * PATIENTS: \>= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America * FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study * FIRST-DEGREE RELATIVES: First-degree relative of proband * FIRST-DEGREE RELATIVES: Resides within the United States * FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant * FIRST-DEGREE RELATIVES: Are fluent in English * FIRST-DEGREE RELATIVES: Age \>= 18 years Exclusion Criteria: * PATIENTS: Unable to provide informed consent * PATIENTS: =\< 2 at-risk first-degree relatives who are eligible for genetic testing and/or reside within the United States * PATIENTS: Unwilling to provide contact information for family members * FIRST-DEGREE RELATIVES: Unable or unwilling to provide informed consent * FIRST-DEGREE RELATIVES: Have undergone genetic testing for the known familial variant * FIRST-DEGREE RELATIVES: Resides outside of the United States

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphoid system neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.